Paolo Madeddu, PhD
|Peter Carmeliet, MD, PhD
Group Leader, Angiogenesis and Vascular Metabolism Laboratory, VIB-KU Leuven Center for Cancer Biology, Belgium
The focus of Professor Carmeliet’s research is on unraveling the molecular basis of angiogenesis and translating these genetic insights into therapeutic concepts and, if possible, novel treatments. Recent findings include a novel approach to block or normalize vessel growth by interfering with the cellular metabolism of the vascular endothelial cells (ECs). The Carmeliet lab is also interested in unraveling the molecular basis of EC dysfunction and EC regeneration.
|Douglas W Losordo, MD
Adjunct Professor of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, USA
Dr Losordo’s major research interests encompass angiogenesis/vasculogenesis, progenitor/adult stem cells, tissue repair/regeneration, and vascular biology. The Losordo group has executed the full translational medicine paradigm: to identify novel therapeutics in the laboratory, develop these strategies in small and large animal models, then design and execute in human clinical trials. Examples include VEGF gene therapy for myocardial ischemia and diabetic neuropathy and CD34+ cell therapy for refractory angina, critical limb ischemia, and severe claudication.
|Anna Randi, PhD
Professor of Cardiovascular Medicine and Head of Section for Vascular Science, National Heart and Lung Institute, Imperial College, London, UK
Professor Randi’s main research interests are in vascular biology and vascular haemostasis. The Randi Lab investigates the molecular pathways that regulate endothelial homeostasis, angiogenesis and vascular stability. Projects in the group focus on three main areas: Transcriptional and epigenetic control of endothelial homeostasis by the ETS transcription factor ERG; von Willebrand Factor regulation of angiogenesis and angiodysplasia; circulating endothelial progenitors (or Blood Outgrowth Endothelial Cells) in regenerative and precision medicine.
|Didier Stainier, PhD
Director, Max Planck Institute for Heart and Lung Research, Department Developmental Genetics, Bad Nauheim, Germany
His research focuses on Zebrafish developmental genetics and organ formation. His lab is currently using the tools of cellular and molecular biology, embryology and genetics to analyze some of the mutations that affect heart formation and function and further the understanding of the cellular and molecular mechanisms underlying early cardiac morphogenesis. The Stainier Group is especially interested in studying early heart induction.
|Andrea Banfi, PhD
Director of Cell and Gene Therapy, University Hospital Basel, Switzerland
Dr Banfi directs the Cell and Gene Therapy where his research focus is the understanding of the basic principles governing the growth of blood vessels and translating this knowledge into the development of novel therapies for ischemic disease, such as myocardial infarction and peripheral ischemia; and controlled vascularization in tissue engineering and regenerative medicine applications. The goal is to restore the blood supply in ischemic tissue, or to ensure the induction of a functional vascular network in tissue engineered constructs, by the delivery of growth factors that control the formation of new blood vessels.
|Tim Chico, MD, PhD
Professor of Cardiovascular Medicine and Honorary Consultant Cardiologist, Head of Department, Department of Infection, Immunity & Cardiovascular Disease, University of Sheffield, UK
The Chico group studies the influence of blood flow on vascular development and remodelling and have identified a number of pathways that integrate sensation of blood flow and vascular development. The group predominantly use zebrafish as a model and more recently have started to use lightsheet imaging allowing incredibly detailed cellular and subcellular imaging of live embryos during vascular development.
|Józef Dulak, PhD
Professor and Head, Department of Medical Biotechnology, Jagiellonian University, Krakow, Poland
The main field of research is vascular biology, with particular interest in molecular mechanisms of angiogenesis, vasculogenesis, inflammation and oxidative stress. The Dulak group is are also interested in tumor cell biology as well as the investigation of gene and cell therapy approaches to treat vascular disorders.
|Jennifer Gamble, PhD
Wenkart Chair of Endothelium Medicine, Centenary Institute of Cancer Medicine & Cell Biology, University of Sydney, Australia
Professor Gamble’s interests lie in understanding endothelial cell function particularly in the area of inflammation, and how dysfunction can influence disease. Diseases being investigated include cancer, atherosclerosis, metabolic disease, oedema and thoracic aortic aneurysms.
|Timothy Hla, PhD
Patricia K. Donahoe Professor, Harvard Medical School, Department of Surgery, Boston Children's Hospital, USA
Tim Hla's laboratory has been investigating the role of lipid mediators, sphingosine 1-phosphate (S1P) and prostanoids in vascular biology and disease. Recent research is examining molecular mechanisms by which prostanoids interact with other lipid signaling systems to protect the vascular system and maintain health. Since their discovery of the S1P receptor, they have been working on how this novel signaling pathway regulates vascular development, homeostasis and is dysregulated in vascular diseases.
|Luisa Iruela-Arispe, PhD
Professor and Vice-chair of the Molecular, Cell and Developmental Biology, Director of the Molecular Biology Institute and Chair of the Molecular Biology Inter-Departmental Graduate Program, UCLA, USA
Dr Iruela-Arispe's research focuses on the molecular mechanisms that regulate angiogenesis during development and in pathological conditions. The Arispe laboratory is currently investigating the mechanisms behind the formation of vascular tumors and vascular anomalies. In particular, the group is interested in the identification of critical regulatory nodes that maintain vascular homeostasis and control endothelial proliferation in the context of flow. An additional focus of the lab is to dissect the molecular interactions between endothelial and tumor cells during the process of metastasis with particular emphasis on endothelial barrier.
|Injune Kim, PhD
Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea
Dr Kim's focus is to further the understanding of transcriptional regulation governing vascular development, vascular homeostasis, and vascular disease. Focus has been on endothelial-specific transcription factors Sox7 and Sox17, which belong to the SoxF subfamily, in order to understand main transcriptional regulation in various vascular contexts. Going forward, Kim's lab is trying to understand vascular changes in the central nervous system, including the brain and retina with the aim of developing therapeutics for glioblastoma and rescue barrier function of CNS vessels.
|Peter J Little, AM, PhD
Professor of Pharmacy and Head, School of Pharmacy, The University of Queensland, Woolloongabba, Queensland, 4102 Australia and Chief Professor and Dean (Visiting), Department of Pharmacy, Xinhua College of Sun Yat sen University, Tianhe District, Guangzhou, 510520, China
Professor Little is the Head of the Diabetes Complications Laboratory at the School of Pharmacy at The University of Queensland, Brisbane, Australia. The main focus of the lab is atherothrombosis with two streams: developing innovative bio-nanomaterials and magnetic resonance imaging (MRI) nanosensors for molecular imaging and drug delivery aimed at identifying and characterising thrombi in cardiovascular disease; another stream studies signalling pathways in vascular smooth muscle as they relate to the expression of the genes which mediate hyperelongation of glycosaminoglycan (GAG) chains on the proteoglycan, biglycan where the binding of lipoproteins to the GAG chains is the initiating step in atherosclerosis under the "response to retention" hypothesis.
|Taija Mäkinen, PhD
Associate Professor, Dept. Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Sweden
The key aim of Prof Mäkinen’s research is to understand how endothelial cells lining blood and lymphatic vessels communicate with each other and the tissue environment to co-ordinate vascular morphogenesis. A second major aim is to understand organ-specific regulation of lymphatic vessel formation and function.
|Naoki Mochizuki MD, PhD
Director General, National Cerebral & Cardiovascular Center Research Institute, Osaka, Japan
Professor Mochizuki's research is focused on the exploration of the molecular mechanism by which blood vessel formation and cardiogenesis are regulated during development with the aim to develop new strategies for cardiovascular regeneration. His group currently uses zebrafish to investigate cardiovascular development and the embyros expressing fluorescent proteins under the cardiovascular-specific promoters are visualized as they develop.
|Seppo Ylä-Herttuala, MD, PhD
Molecular Medicine Group Leader, University of Eastern Finland, Kuopio, Finland
Dr Ylä-Herttuala is focused on developing new gene and protein-based approaches for the treatment of cardiovascular diseases. His group was the first in the world to use direct adenoviral gene transfer to human arteries in vivo in 1996. Major achievements include the discovery of the vasculoprotective effect of VEGF gene therapy, characterization of the vascular effects of the new members of the VEGF family including their effects on lymphatic vessels, and identification of several new candidate genes for the treatment of vascular diseases.
|Danielle Kamato, PhD
School of Pharmacy, University of Queensland, Australia
Note that we are still in the process of recruiting editors for Vascular Biology so this list will evolve.
Editors' declarations are listed in the journal's Disclosure Policy.